Bsx stock price dipped to $72

BSX stock price dipped to $72.75 amid profit-taking activity. Still, most brokerage forecasts see upside potential toward $78 as new neuromodulation systems capture market attention. The company also reported GAAP net income attributable to common stockholders of $797 million or $0.53 per share (EPS), compared to $324 million or $0.22 per share a year ago. Valuation is also important, so investors should note that Boston Scientific has a Forward P/E ratio of 36.32 right now. This represents a premium compared to its industry average Forward P/E of 19.01. Trading sessions saw BSX stock price steady at $73.50, supported by a positive revision in industry-wide medtech forecasts. Investors continue to monitor innovation cycles for sustainable returns.